The launch of Dupixent, pediatric vaccine sales and continued growth in Sanofi’s multiple sclerosis franchise were the strongest revenue drivers in third-quarter 2017.
More than half of patients with a rare genetic disorder experienced significant improvement after being treated with an Alnylam drug that uses gene silencing technology.
Teva Pharmaceutical Industries said it would miss 2017 profit forecasts due to competition in the U.S. market and weakening sales of the company’s multiple sclerosis drug Copaxone, hammering shares for the world’s largest generic medicine maker.
The U.S. FDA’s Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 18-to-1 to recommend Indivior’s RBP-6000 to treat opioid use disorder.
AstraZeneca stepped up its bet on immunotherapy combo treatments to fight lung cancer by signing a deal with Incyte as they will start a final-stage study in 2018.
Merck announced that the company pulled its application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer from the European Medicines Agency.
AbbVie expect its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.
Merck & Co. reported profit ahead of Street estimates on strong sales of its cancer drug Keytruda, but total revenue fell in third-quarter 2017 from disruptions due to the NotPetya cyber attack and loss of market share for many of the company’s older drugs.
In the company’s third-quarter 2017 report, Amgen Inc. announced it scrapped internal development of AMG 899, an oral CETP inhibitor it acquired in the $1.2 billion deal for Netherlands-based Dezima Pharma BV.
Ghent, Belgium-based Ablynx NV announced the price of its U.S. initial public offering (IPO) at $17.50.